

CELGENE CORP /DE/  
Form 8-K  
June 19, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 19, 2018**

**CELGENE CORPORATION**

**(Exact name of registrant as specified in its charter)**



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

**ITEM 8.01 OTHER EVENTS**

On June 19, 2018, Celgene Corporation announced that Jonathan Biller will succeed Gerald F. Masoudi as Executive Vice President and General Counsel effective July 3, 2018. Mr. Masoudi is leaving Celgene to return to Washington, D.C. with his family and assume the role of Chief Legal Officer with a private company outside of the biopharmaceutical industry.

Attached hereto and incorporated by reference as Exhibit 99.1 is the Press Release announcement.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

Exhibit 99.1 – Press Release dated June 19, 2018

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: June 19, 2018 By: /s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President and Chief Financial Officer  
(Principal Financial and Accounting Officer)